SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J
$CHRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ] | 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| |||||||||||||||||||||||||
| 2a. Foreign Trading Symbol
| |||||||||||||||||||||||||||
| 3. Date of Earliest Transaction
(Month/Day/Year) 05/29/2026 | 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed
(Month/Day/Year) |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $14.76 | 05/29/2026 | D | 100,000 | (1) | 04/28/2031 | Common Stock | 100,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $14.67 | 05/29/2026 | D | 25,000 | (1) | 01/07/2032 | Common Stock | 25,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $10.78 | 05/29/2026 | D | 15,000 | (2) | 09/07/2032 | Common Stock | 15,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $9.87 | 05/29/2026 | D | 25,000 | (3) | 01/04/2033 | Common Stock | 25,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $6 | 05/29/2026 | D | 25,000 | (4) | 03/27/2033 | Common Stock | 25,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $5.44 | 05/29/2026 | D | 30,000 | (1) | 06/13/2033 | Common Stock | 30,000 | (5) | 0 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 100,000 | (1) | 05/29/2036 | Common Stock | 100,000 | (5) | 100,000 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 25,000 | (1) | 05/29/2036 | Common Stock | 25,000 | (5) | 25,000 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 15,000 | (2) | 05/29/2036 | Common Stock | 15,000 | (5) | 15,000 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 25,000 | (3) | 05/29/2036 | Common Stock | 25,000 | (5) | 25,000 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 25,000 | (4) | 05/29/2036 | Common Stock | 25,000 | (5) | 25,000 | D | ||||
| Stock Option (Right to Buy) | $1.59(6) | 05/29/2026 | A | 30,000 | (1) | 05/29/2036 | Common Stock | 30,000 | (5) | 30,000 | D | ||||
| Explanation of Responses: |
| 1. The option is fully vested and exercisable. |
| 2. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from September 7, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| 3. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| 4. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 27, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| 5. On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged. |
| 6. On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. |
| /s/ Bryan McMichael | 06/02/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 4: SEC 1474 (03-26) | ||